Impact of Combining Brain Radiotherapy with Immunotherapy and Chemotherapy in NSCLC

Overview

This study evaluates the efficacy of brain radiotherapy combined with immunotherapy and chemotherapy in driver gene-negative NSCLC patients with brain metastases. Results indicate a median overall survival of 19.6 months for patients receiving the combined treatment compared to 15 months for those receiving chemotherapy alone.

Background

Brain metastases are common in advanced non-small cell lung cancer (NSCLC), significantly impacting patient prognosis. Patients lacking driver genes face limited treatment options, as conventional therapies may not be effective. The combination of immunotherapy with traditional treatments may offer new avenues for improving outcomes in this challenging patient population.

Data Highlights

Key Findings

• The RT+CT+ICI group had a median overall survival of 19.6 months compared to 15 months in the RT+CT group.
• Multivariable adjustments confirmed prolonged overall survival (HR 0.58, P = 0.002) and progression-free survival (HR 0.72, P = 0.038) in the RT+CT+ICI group.
• Stereotactic radiosurgery (SRS) is identified as a protective factor for overall survival in these patients.
• PD-L1 expression is associated with better progression-free survival and intracranial progression-free survival.
• Patients with driver gene-negative NSCLC often lack effective targeted therapies, necessitating alternative treatment strategies.
• The study provides real-world data to inform clinical decision-making for this patient population.

Clinical Implications

The findings indicate that combining brain radiotherapy with immunotherapy and chemotherapy may enhance survival outcomes for driver gene-negative NSCLC patients with brain metastases.

Conclusion

This study demonstrates the efficacy of combining brain radiotherapy with immunotherapy and chemotherapy in driver gene-negative NSCLC patients with brain metastases.

Related Resources & Content

1. ASCO Post, 2020 -- Addition of Immunotherapy to Other Treatments in Patients With Brain Metastases After Definitive Surgery
2. Frontiers in Immunology, 2026 -- Stereotactic versus whole-brain radiotherapy combined with immunotherapy in driver gene–negative NSCLC with brain metastases: a real-world IPTW analysis
3. ASCO Post, 2016 -- Which Factors Influence Radiotherapy for Brain Metastases?
4. ASCO Post, 2025 -- Advanced NSCLC With Brain Metastases: Potential Novel Therapeutic Option
5. Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline - PMC
6. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer
7. Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline - PMC
8. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer | Journal of Clinical Oncology
9. Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: An international meta-analysis of individual patient data - Penn State